BACKGROUND: Glioblastoma (GBM) is the most common primary malignant human brain tumor with a poor prognosis. The diagnosis of GBM is based on histological features, however, few studies have evaluated their prognostic relevance in light of the latest WHO classification of 2007. AIM: In this study we have evaluated the prognostic value of several clinical and histological characteristics encountered in human GBMs according to the WHO 2007 criteria. MATERIAL AND METHODS: 199 patients with primary GBM consecutively operated and histologically reviewed according to the 2007 WHO scheme, were included. Several clinical and histological features were recorded and related to survival. RESULTS: Mean age of the GBM patients at diagnosis was 62 years (range 21 - 84). Male/female ratio was 1.3/1, and the median survival was 8.0 months (95% CI: 7.1 - 9.0 months). In a multivariate COX analysis age, WHO performance score, subcortical localization, extent of surgery, radiation treatment, chemotherapy, and the presence of large necrosis had individual effect on overall survival (p < 0.05). In addition, females, tumors with angiocentric growth, with pseudopalisades, or without lymphocyte infiltration were related to shorter survival in univariate analyses (p < 0.05). CONCLUSION: Our findings confirm the strong prognostic value of age, treatment, performance score, and localization for glioblastoma patients. Amongst the histopathological features only large necrosis was an independent prognostic factor.
BACKGROUND:Glioblastoma (GBM) is the most common primary malignant humanbrain tumor with a poor prognosis. The diagnosis of GBM is based on histological features, however, few studies have evaluated their prognostic relevance in light of the latest WHO classification of 2007. AIM: In this study we have evaluated the prognostic value of several clinical and histological characteristics encountered in human GBMs according to the WHO 2007 criteria. MATERIAL AND METHODS: 199 patients with primary GBM consecutively operated and histologically reviewed according to the 2007 WHO scheme, were included. Several clinical and histological features were recorded and related to survival. RESULTS: Mean age of the GBM patients at diagnosis was 62 years (range 21 - 84). Male/female ratio was 1.3/1, and the median survival was 8.0 months (95% CI: 7.1 - 9.0 months). In a multivariate COX analysis age, WHO performance score, subcortical localization, extent of surgery, radiation treatment, chemotherapy, and the presence of large necrosis had individual effect on overall survival (p < 0.05). In addition, females, tumors with angiocentric growth, with pseudopalisades, or without lymphocyte infiltration were related to shorter survival in univariate analyses (p < 0.05). CONCLUSION: Our findings confirm the strong prognostic value of age, treatment, performance score, and localization for glioblastomapatients. Amongst the histopathological features only large necrosis was an independent prognostic factor.
Authors: Rahimsan K Ramachandran; Mia D Sørensen; Charlotte Aaberg-Jessen; Simon K Hermansen; Bjarne W Kristensen Journal: PLoS One Date: 2017-02-24 Impact factor: 3.240
Authors: Celina Garcia; Luiz Gustavo Dubois; Anna Lenice Xavier; Luiz Henrique Geraldo; Anna Carolina Carvalho da Fonseca; Ana Helena Correia; Fernanda Meirelles; Grasiella Ventura; Luciana Romão; Nathalie Henriques Silva Canedo; Jorge Marcondes de Souza; João Ricardo Lacerda de Menezes; Vivaldo Moura-Neto; Fernanda Tovar-Moll; Flavia Regina Souza Lima Journal: BMC Cancer Date: 2014-12-08 Impact factor: 4.430